Impact of using time-averaged exposure metrics on binary endpoints in exposure-response analyses Publication Impact of using time-averaged exposure metrics on binary endpoints in exposure-response analyses This Frontiers in Pharmacology article investigates how using different time-averaged exposure metrics, specifically the time-averaged…Certara2025年1月21日
Solving Drug Development Challenges with Model-Based Meta-Analysis (MBMA) On-Demand Webinar Solving Drug Development Challenges with Model-Based Meta-Analysis (MBMA) In this on-demand webinar, "MBMA: Optimizing Drug Development with Aggregate Clinical Trial Data and Predictive…Certara2025年1月9日
INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer’s disease Publication INTERCEPT-AD:アルツハイマー病による軽度認知障害または軽度認知症の被験者を対象とした、サビルネトゥグ静脈内投与のフェーズ1試験 The Phase 1 INTERCEPT-AD study evaluated sabirnetug (ACU193), a monoclonal antibody targeting amyloid-beta oligomers (AβOs),…Certara2025年1月8日
Population Pharmacokinetics (PopPK) of Revumenib in Patients with Relapsed/Refractory Acute Leukemias Poster Population Pharmacokinetics (PopPK) of Revumenib in Patients with Relapsed/Refractory Acute Leukemias Certara2024年12月12日
Piet van der Graaf on AI and AI-assisted approaches in drug discovery & development Video Piet van der Graaf on AI and AI-assisted approaches in drug discovery & development At the 2024 AAPS PharmSci 360 conference, Bioanalysis Zone interviewed Piet van der Graaf, Senior…Certara2024年12月10日
Advancing pharmacometrics in Africa – Transition from capacity development toward job creation Publication Advancing pharmacometrics in Africa – Transition from capacity development toward job creation This CPT article showcases, the Applied Pharmacometrics Training (APT) program, launched in 2021 by Pharmacometrics…Certara2024年12月9日
Population K-PD Modeling of Plozasiran (ARO-APOC3), a GalNAc-siRNA Conjugate, for the Treatment of Patients with Severe Hypertriglyceridemi Poster Population K-PD Modeling of Plozasiran (ARO-APOC3), a GalNAc-siRNA Conjugate, for the Treatment of Patients with Severe Hypertriglyceridemi Certara2024年11月22日
Population pharmacokinetic modeling of TBA-7371 in healthy participants describes apparent auto-induction of clearance and predicts PK in participants with Mycobacterium tuberculosis. ポスター Population pharmacokinetic modeling of TBA-7371 in healthy participants describes apparent auto-induction of clearance and predicts PK in participants with Mycobacterium tuberculosis. Certara2024年11月22日
Impacts of dose titration on logistic exposure-response in simulated flexible-dose clinical trials Poster Impacts of dose titration on logistic exposure-response in simulated flexible-dose clinical trials Certara2024年11月22日
Simultaneous Population PKPD Analysis of Belantamab Mafodotin, Soluble BCMA, and Serum M-Protein in Subjects With Relapsed/Refractory Multiple Myeloma Poster Simultaneous Population PKPD Analysis of Belantamab Mafodotin, Soluble BCMA, and Serum M-Protein in Subjects With Relapsed/Refractory Multiple Myeloma Certara2024年11月22日